Nanoparticle imaging startup Alzeca reels in $11M for Alzheimer's diagnostic

Money
Alzeca will use its series A funding to carry its nanoparticle contrast agent through a phase 1 trial.

Alzeca Biosciences raised $11 million in series A financing that will bolster the development of its MRI-based nanoparticle contrast agent, designed for the early detection of Alzheimer’s disease and other neurodegenerative disorders.

The ADx nanoparticle targets amyloid plaques in the brain, a hallmark of Alzheimer’s. The funding will put the candidate through a phase 1 trial and support the development of imaging agents that target other Alzheimer’s-linked brain proteins. The company is also interested in creating imaging agents to detect proteins linked to other diseases, such as chronic traumatic encephalopathy (CTE), which is currently only diagnosed after death.

There is no single test to diagnose Alzheimer’s, but positron-emission tomography (PET) imaging may be used to detect amyloid deposits in the brain. But PET imaging is expensive, not widely available and exposes patients to high doses of radiation, Alzeca said. The Houston-based company hopes that ADx, which uses commonly available MRI technology, will improve access to Alzheimer’s diagnosis. In addition to catching symptoms early, an MRI-based diagnostic does not subject patients to radiation.

The MedTech Conference

The MedTech Conference: September 23-25, Boston, MA

With over 3,000 attendees from 35 countries, The MedTech Conference features world-class plenary speakers, cross-cutting educational programming and business development opportunities. This is a prime opportunity to network, conduct business and share insights with medtech leaders. Register before July 26th and save $200!

“The ability to diagnose neurodegenerative diseases such as Alzheimer’s years before serious cognitive impairment manifests, so as to potentially intervene therapeutically at an early stage in the disease process, is a significant healthcare challenge,” said Peter Werth, CEO of Chemwerth, who joined Alzeca’s board of directors, in the statement. “We are excited to partner with Alzeca because its promising MRI brain imaging agents offer great potential not only to advance the early diagnosis of such conditions but also to aid in monitoring patient response to treatment both during drug development and in the clinic.”

Akili Interactive, which is working on video game-based diagnostics and therapies, reported last December that its platform could tell the difference between patients with and without brain amyloidosis. Akili’s diagnostic tool takes the form of a fast-paced action game on a tablet. The company hopes the “digital biomarkers” it measures could become a noninvasive option to screen for amyloid plaques in the brain.

Suggested Articles

Eisai showed correlations between amyloid biomarkers in the blood and cerebrospinal fluid, bringing it closer to a simple blood test for Alzheimer’s.

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

The series A sets ex-Gilead R&D chief Norbert Bischofberger up to advance efforts to hit historically undruggable targets.